LMO3 and breast carcinoma: For example, miR-381 inhibits the proliferation and invasion of prostate cancer cells via the regulation of UBE2C [41]; miR-381 inhibits lung adenocarcinoma progression by directly targeting LMO3 through the regulation of the PI3K/Akt signaling pathway and EMT [42]; up-regulation of miR-381 inhibits the NAD+ salvage pathway and promotes apoptosis in breast cancer cells [43]; miR-381 overcomes cisplatin resistance in breast cancer cells by targeting MDR1 [44].